On April 28, Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced that it acquired Clinical Research Strategy Group, LLC, and Precision Research. These two clinical trial optimization companies focus on streamlining and speeding the drug development process for inflammatory bowel disease (IBD).
Through this acquisition, Iterative Scopes’ ties to the IBD clinical research community are deepened, and its knowledge of the end-to-end research process keeping in mind the provider viewpoints and pain points, has been strengthened. It will improve patient outcomes by providing improved treatment options. Chris Fourment, MD, the President, and CEO of both the companies, is a leading expert on clinical trials in IBD. He has joined Iterative Scopes as SVP of Clinical Strategy.
Founded in 2017, Iterative Scopes was a spin-out of the Massachusetts Institute of Technology (MIT) by Dr. Ng, a physician-entrepreneur who developed the company’s foundational concepts while studying at MIT and Harvard. In December 2021, the company and its investors closed a $150 million Series B funding. It attracted a roster of A-list venture capitalists, big pharma companies, and leaders in healthcare.
“I am excited to join Iterative Scopes to help the organization further harness machine learning and computer vision to aid physicians as they work to improve clinical outcomes for IBD patients earlier and with greater success. The current clinical trial process for IBD drug development has patient recruitment and clinical team workflow challenges. Iterative Scopes is employing cutting-edge computational algorithms and support services that have the potential to resolve these challenges.”
Iterative Scopes founder and CEO Dr. Jonathan Ng said, “With the addition of CRSG and Precision, Iterative Scopes has the opportunity to work more closely with different types of clinical trial sites and providers and to gain sophisticated insights about their needs and pain points, with the goal of refining our ground-breaking AI Recruitment service. Community sites face different challenges and opportunities than other types of providers, and these acquisitions help us create an intimate, holistic and fulsome knowledge of all stakeholders involved in the research process. While I have known Chris for some time now, we are thrilled to finally have him aboard our team, bringing his globally renowned expertise in IBD research to Iterative Scopes."